Arie Belldegrun details 5.8% Allogene (ALLO) stake via multiple entities

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. shareholder Arie Belldegrun reports beneficial ownership of 13,248,170 shares of common stock, equal to 5.8% of the company as of December 31, 2025. This total includes 3,885,280 shares issuable within 60 days upon exercise of stock options.

The filing aggregates shares held directly and through Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P. Ownership percentages are calculated using 224,730,144 Allogene shares outstanding as of November 4, 2025.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

019770106

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Arie Belldegrun, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,475,883.00
6	Shared Voting Power 8,772,287.00
7	Sole Dispositive Power 4,475,883.00
8	Shared Dispositive Power 8,772,287.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,248,170.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Bellco Legacy LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 539,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 539,867.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

539,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Bellco Legacy IV LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,710,120.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,710,120.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,710,120.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Vida Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,798,163.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,798,163.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,798,163.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Vida Ventures III, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,720,172.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,720,172.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,720,172.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.8 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 019770106

1

Names of Reporting Persons

Vida Ventures III-A, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,965.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Allogene Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 210 East Grand Avenue, South San Francisco, CA, 94080.
Item 2.
(a)	Name of person filing: Arie Belldegrun Bellco Legacy LLC Bellco Legacy IV LLC Vida Ventures LLC Vida Ventures III, L.P. Vida Ventures III-A, L.P.
(b)	Address or principal business office or, if none, residence: Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109
(c)	Citizenship: Arie Belldegrun: United States and Israel Bellco Legacy LLC: Delaware Bellco Legacy IV LLC: Delaware Vida Ventures LLC: Nevada Vida Ventures III, L.P.: Nevada Vida Ventures III-A, L.P.: Nevada
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 019770106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Belldegrun's cover page includes 3,885,280 shares of common stock issuable within 60 days of December 31, 2025 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 224,730,144 shares of common stock outstanding as of November 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 6, 2025.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Arie Belldegrun, M.D.

Signature:	/s/ Arie Belldegrun
Name/Title:	Arie Belldegrun, M.D.
Date:	02/17/2026

Bellco Legacy LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	02/17/2026

Bellco Legacy IV LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	02/17/2026

Vida Ventures LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:	02/17/2026

Vida Ventures III, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:	02/17/2026

Vida Ventures III-A, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	02/17/2026

Exhibit Information

Joint Filing Agreement

FAQ

How large is Arie Belldegrun’s stake in Allogene Therapeutics (ALLO)?

Arie Belldegrun reports beneficial ownership of 13,248,170 Allogene common shares, representing 5.8% of the company. This figure includes shares held directly, shares held through affiliated entities, and stock options exercisable within 60 days of December 31, 2025, as detailed in the ownership breakdown.

Which entities are included in the joint Schedule 13G/A filing for Allogene (ALLO)?

The joint filing covers Arie Belldegrun, Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P. Each entity reports its own share counts and percentage of Allogene common stock, with Belldegrun signing on behalf of the various managers.

What percentage of Allogene (ALLO) does each reporting Vida Ventures entity own?

Vida Ventures LLC reports beneficial ownership of 1,798,163 shares, or 0.8% of Allogene. Vida Ventures III, L.P. reports 1,720,172 shares, also 0.8%, and Vida Ventures III-A, L.P. reports 3,965 shares, effectively 0.0% of the common stock class, based on the stated share count.

How are Bellco Legacy entities invested in Allogene Therapeutics (ALLO)?

Bellco Legacy LLC reports 539,867 Allogene shares, or 0.2% of the common stock. Bellco Legacy IV LLC reports 4,710,120 shares, or 2.1%. These holdings are included in Arie Belldegrun’s aggregate beneficial ownership through his management or control of the respective limited liability companies.

What role do stock options play in Arie Belldegrun’s Allogene (ALLO) ownership?

Belldegrun’s reported 13,248,170-share beneficial stake includes 3,885,280 Allogene shares issuable within 60 days of December 31, 2025 upon exercise of stock options. These option shares are counted because they can be acquired in the near term, under SEC beneficial ownership rules.

What share count did the Allogene (ALLO) Schedule 13G/A use to calculate ownership percentages?

Ownership percentages are based on 224,730,144 Allogene common shares outstanding as of November 4, 2025. This outstanding share count comes from the company’s Form 10-Q filed on November 6, 2025, and is used uniformly to compute each reporting person’s percentage of the class.